Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
Boris TchernychevHuihui LiSung-Kyun LeeXin GaoRaghunath RamanarasimhaiahGuang LiuKatherine C HallSylvie G BernierJuli E JonesSusanne FeilRobert FeilEmmanuel S BuysRegina M GraulPaul S FrenetteJaime L MasferrerPublished in: British journal of pharmacology (2021)
Our results suggest that the sGC stimulator olinciguat attenuates inflammation, vaso-occlusion and kidney injury in mouse models of SCD and systemic inflammation.